Autolus Therapeutics (AUTL) AI Stock Analysis

• Market Cap: $614.79M
• Dividend Yield: N/A
• Average Volume (3M): 2.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: -14.16%
• EPS Growth: 25.80%
• Country: US
• Employees: 647
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 266,141,420
• 10 Day Avg. Volume: 1,953,652
• 30 Day Avg. Volume: 2,244,819
• PEG Ratio: 0.06
• Price to Book (P/B): 0.60
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.47
• Enterprise Value/Market Cap: -0.29
• Enterprise Value/Revenue: -4.11
• Enterprise Value/Gross Profit: 7.25
• Enterprise Value/Ebitda: 0.23
• 1Y Price Target: $10.00
• Price Target Upside: 338.60% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 53 Neutral
• Price Target: $2.00 ▼(-12.28%Downside)

The overall stock score of 53 is largely influenced by weak financial performance due to ongoing operational losses and cash flow issues. Despite a strong technical analysis and positive earnings call sentiment, the company's financial challenges weigh heavily on the score. The valuation is also impacted by the negative P/E ratio, highlighting the need for improved profitability.

Positive Factors

Financial Performance

Autolus reported an impressive $9.0 million in sales for Aucatzyl in the first quarter, substantially beating our estimate of $2.9 million.

Product Adoption

These findings could potentially lead to more rapid commercial uptake of obe-cel.

Negative Factors

Regulatory Challenges

Receiving a positive NICE opinion will be important for achieving widespread payor coverage.

Autolus Therapeutics Business Overview & Revenue Model

Company Description

Autolus Therapeutics (AUTL) is a clinical-stage biopharmaceutical company focusing on the development of next-generation, programmed T cell therapies for the treatment of cancer. The company specializes in engineering T cells to recognize and attack cancer cells, leveraging its proprietary T cell programming technology. Autolus aims to offer innovative solutions in the field of oncology, targeting hematological malignancies and solid tumors.

How the Company Makes Money

Autolus Therapeutics primarily generates revenue through research and development collaborations, strategic partnerships, and licensing agreements with other biotechnology and pharmaceutical companies. These partnerships often involve upfront payments, milestone payments, and royalties on sales of any successfully commercialized therapies. The company also seeks funding through public and private offerings of equity securities to support its clinical trials and research activities. As a clinical-stage company, Autolus does not yet generate revenue from product sales, as its therapies are still under development and regulatory approval processes.

Autolus Therapeutics Financial Statement Overview

Summary

Autolus Therapeutics is experiencing revenue growth but continues to face challenges with profitability and cash flow management. Despite strong cash reserves and a low debt-to-equity ratio, negative margins and operational losses highlight financial struggles.

Income Statement

Autolus Therapeutics has shown significant revenue growth in recent years, with a notable increase from $1.7M in 2023 to $10.1M in 2024. However, the company continues to report negative gross and net profit margins, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are also negative, reflecting substantial operational losses.

Balance Sheet

The company's balance sheet highlights a strong equity position, with a substantial cash reserve relative to its liabilities. The debt-to-equity ratio is low at 0.12, suggesting limited leverage, but the company has consistently negative net income affecting ROE, which remains negative. The equity ratio is relatively stable, indicating a solid asset structure.

Cash Flow

Autolus Therapeutics is facing challenges with negative free cash flow, which has worsened in recent periods. Although operating cash flow is negative, it is supported by financing activities, indicating reliance on external funding. The free cash flow to net income ratio is unfavorable, reflecting difficulties in converting income into cash.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.01M	10.12M	1.70M	6.19M	2.33M	242.00K
Gross Profit	-24.52M	-1.27M	-4.87M	-131.03M	-126.32M	-134.65M
EBITDA	-235.74M	-182.42M	-156.77M	-135.54M	-132.01M	-160.51M
Net Income	-238.13M	-220.66M	-208.38M	-148.84M	-142.10M	-142.09M
Balance Sheet
Total Assets	746.34M	782.73M	375.38M	490.27M	405.56M	294.24M
Cash, Cash Equivalents and Short-Term Investments	516.58M	588.02M	239.57M	382.44M	310.34M	153.30M
Total Debt	57.71M	52.63M	52.97M	24.26M	21.00M	54.16M
Total Liabilities	375.23M	355.40M	263.91M	191.60M	92.24M	84.20M
Stockholders Equity	371.11M	427.32M	111.47M	298.67M	313.32M	210.03M
Cash Flow
Free Cash Flow	-283.85M	-241.09M	-156.57M	-123.15M	-126.72M	-132.44M
Operating Cash Flow	-241.32M	-206.27M	-145.59M	-112.31M	-117.86M	-117.76M
Investing Cash Flow	-453.57M	-394.55M	-10.99M	-10.84M	-8.86M	-14.68M
Financing Cash Flow	28.11M	589.55M	-883.00K	223.61M	284.06M	74.42M

Autolus Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.28
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Positive. The current price of 2.28 is above the 20-day moving average (MA) of 2.19, above the 50-day MA of 1.73, and below the 200-day MA of 2.47, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 66.62 is Neutral, neither overbought nor oversold. The STOCH value of 88.66 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUTL.

Autolus Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	60 Neutral	HK$15.14B	5.56	-7.43%	4.30%	11.60%	-21.06%
AUTL	53 Neutral	$614.79M	―	-49.97%	―	-14.16%	25.80%
ALT	53 Neutral	$283.87M	―	-57.28%	―	-95.12%	21.09%
ABSI	52 Neutral	$334.21M	―	-48.98%	―	-9.95%	20.78%
TRML	45 Neutral	$424.89M	―	-26.14%	―	―	74.59%
RAPP	44 Neutral	$417.17M	―	-33.14%	―	―	―
CELC	44 Neutral	$474.84M	―	-115.39%	―	―	-4.14%

Autolus Therapeutics Corporate Events

Autolus Therapeutics Passes All AGM Resolutions

On June 26, 2025, Autolus Therapeutics held its Annual General Meeting where all nine proposed resolutions were passed. Key resolutions included the adoption of the 2024 Annual Report, approval of the Directors’ remuneration report and policy, re-appointment of Ernst & Young LLP as auditors, re-election of Dr. R Iannone and Dr. R Rao as Directors, and the approval of the Employee Share Purchase Plan.

The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Autolus Therapeutics Releases UK Annual Report 2024

On June 2, 2025, Autolus Therapeutics plc released its UK Annual Report and Accounts for the year ending December 31, 2024, and announced its upcoming annual general meeting scheduled for June 26, 2025. Citibank, as the depositary bank for Autolus’s American Depositary Shares, began distributing voting materials to ADS holders, allowing them to instruct the bank on voting their shares, although there may be limitations affecting timely voting.

The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Autolus Therapeutics Directors Announce Departure Plans

On May 23, 2025, Drs. Joseph Anderson and Martin Murphy announced their decision not to seek re-election to the Board of Directors of Autolus Therapeutics at the upcoming Annual General Meeting. Their resignation is not due to any disagreements with the company’s management or board, suggesting a smooth transition and stability within the company’s governance structure.

The most recent analyst rating on (AUTL) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Autolus Therapeutics stock, see the AUTL Stock Forecast page.

Autolus Therapeutics Reports Q1 2025 Financial Results

Autolus Therapeutics reported its financial results for the first quarter of 2025, highlighting a net product revenue of $9.0 million from AUCATZYL® and securing marketing authorization from the U.K.’s MHRA. The company is advancing its clinical trials, including a Phase 2 trial for lupus nephritis and a Phase 1 trial for multiple sclerosis, with plans to dose the first patients by the end of 2025. Despite a net loss of $70.2 million for the quarter, Autolus remains well-capitalized to support its ongoing and planned clinical developments, aiming to expand its therapeutic reach and address significant unmet medical needs.

Autolus Therapeutics to Present R&D Update April 23

On April 23, 2025, Autolus Therapeutics will present a corporate update at an R&D investor event, which will be accessible via a live webcast and archived on the company’s website. This presentation may impact the company’s operations and industry positioning by providing stakeholders with insights into its ongoing research and development efforts.

Autolus Therapeutics Announces Leadership Transition in Finance

On February 24, 2025, Autolus Therapeutics announced the resignation of Andrew Mercieca, Vice President of Finance and principal accounting officer, effective August 2025. His departure is amicable and not due to any disagreements with the company. On April 3, 2025, the Board appointed Rob Dolski, the current CFO, as the new principal accounting officer, consolidating his roles without additional compensation, indicating a seamless transition in leadership.